{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:28:04Z","timestamp":1791851284832,"version":"4.3.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["XMLX201837"],"award-info":[{"award-number":["XMLX201837"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["XXT26"],"award-info":[{"award-number":["XXT26"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10302-206-003-006"],"award-info":[{"award-number":["2018ZX10302-206-003-006"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.aohep.2020.09.012","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T12:26:51Z","timestamp":1602505611000},"page":"100268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Liwei","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibo","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weini","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-9669","authenticated-orcid":false,"given":"Huichun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2020.09.012_bib0005","series-title":"Hepatitis C fact sheet","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.aohep.2020.09.012_bib0010","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-019-00774-0","article-title":"Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A. 2019 Update","volume":"58","author":"Smolders","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.aohep.2020.09.012_bib0015","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/MEG.0000000000001376","article-title":"Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan","volume":"31","author":"Sarwar","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0020","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.lpm.2018.06.019","article-title":"Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH)","volume":"48","author":"Pariente","year":"2019","journal-title":"Presse Med"},{"key":"10.1016\/j.aohep.2020.09.012_bib0025","first-page":"8","article-title":"SVR12 higher than 97% in GT3 cirrhotic patients with evidence of portal hypertension treated with SOF\/VEL without ribavirin: A nation-wide cohort study","author":"Mangia","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.aohep.2020.09.012_bib0030","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/jmv.25552","article-title":"Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort","volume":"91","author":"Macken","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0035","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.aohep.2019.08.001","article-title":"Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil","volume":"18","author":"Lobato","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0040","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs","volume":"71","author":"Llaneras","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0045","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/jvh.13133","article-title":"High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar","volume":"26","author":"Hlaing","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.aohep.2020.09.012_bib0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12985-019-1184-y","article-title":"High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting","volume":"16","author":"Han","year":"2019","journal-title":"Virol J"},{"key":"10.1016\/j.aohep.2020.09.012_bib0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/nep.13222","article-title":"Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL\/min","volume":"24","author":"Goel","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.aohep.2020.09.012_bib0060","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous daa failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"Journal of hepatology"},{"key":"10.1016\/j.aohep.2020.09.012_bib0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C","volume":"70","author":"D\u2019Ambrosio","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.aohep.2020.09.012_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.12669\/pjms.35.2.637","article-title":"Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience","volume":"35","author":"Butt","year":"2019","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.aohep.2020.09.012_bib0075","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.aohep.2020.09.012_bib0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhep.2018.09.018","article-title":"Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir\/sofosbuvir in hepatitis C genotype 2 and 3","volume":"70","author":"Belperio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0085","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jvh.13115","article-title":"Real-world effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients","volume":"26","author":"Belperio","year":"2019","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.aohep.2020.09.012_bib0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.aohep.2018.09.004","article-title":"Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience","volume":"18","author":"Araujo","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jmv.24903","article-title":"Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)","volume":"90","author":"Wehmeyer","year":"2018","journal-title":"J Med Virol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0100","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"von Felden","year":"2018","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1016\/j.aohep.2020.09.012_bib0105","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12985-018-1066-8","article-title":"Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study","volume":"15","author":"Tao","year":"2018","journal-title":"Virol J"},{"key":"10.1016\/j.aohep.2020.09.012_bib0110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.transproceed.2018.02.001","article-title":"Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study","volume":"50","author":"Mucenic","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.aohep.2020.09.012_bib0115","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/QAD.0000000000001699","article-title":"Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients","volume":"32","author":"M\u00ednguez","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.aohep.2020.09.012_bib0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jceh.2017.06.003","article-title":"Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India","volume":"8","author":"Mehta","year":"2018","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jmv.25033","article-title":"Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study","volume":"90","author":"Marciano","year":"2018","journal-title":"J Med Virol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0130","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/jvh.12989","article-title":"Findings from a large Asian chronic hepatitis C real-life study","volume":"25","author":"Lim","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.aohep.2020.09.012_bib0135","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/hep4.1156","article-title":"Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease\/cirrhosis in a real-world cohort","volume":"2","author":"Kwo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.aohep.2020.09.012_bib0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3851\/IMP3108","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease","volume":"22","author":"Rockstroh","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.aohep.2020.09.012_bib0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/QAI.0000000000001342","article-title":"Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV\/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort","volume":"75","author":"Lacombe","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.aohep.2020.09.012_bib0150","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/liv.13383","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme","volume":"37","author":"Hezode","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2020.09.012_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179764","article-title":"Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study","volume":"12","author":"Dalgard","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2020.09.012_bib0160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.13925","article-title":"Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection","volume":"45","author":"Cornberg","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2020.09.012_bib0165","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/17474124.2017.1292850","article-title":"Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program","volume":"11","author":"Gray","year":"2017","journal-title":"Expert Review of Gastroenterology and Hepatology"},{"key":"10.1016\/j.aohep.2020.09.012_bib0170","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil","volume":"16","author":"Cheinquer","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.aohep.2020.09.012_bib0175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jvh.12648","article-title":"Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort","volume":"24","author":"Alonso","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.aohep.2020.09.012_bib0180","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.aohep.2020.09.012_bib0185","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.09.012_bib0190","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2020.09.012_bib0195","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.aohep.2020.09.012_bib0200","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2020.09.012_bib0205","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.aohep.2020.09.012_bib0210","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aohep.2020.09.012_bib0215","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aohep.2020.09.012_bib0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J Clin Virol."},{"key":"10.1016\/j.aohep.2020.09.012_bib0225","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotpye 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med."}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268120301836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268120301836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:42:20Z","timestamp":1761648140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268120301836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":45,"alternative-id":["S1665268120301836"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2020.09.012","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2020.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C.","name":"copyright","label":"Copyright"}],"article-number":"100268"}}